{"nctId":"NCT00322556","briefTitle":"Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)","startDateStruct":{"date":"2005-11"},"conditions":["Agammaglobulinemia","IgG Deficiency","Common Variable Immunodeficiency"],"count":55,"armGroups":[{"label":"IgPro10","type":"EXPERIMENTAL","interventionNames":["Drug: Immunoglobulins Intravenous (Human)"]}],"interventions":[{"name":"Immunoglobulins Intravenous (Human)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\nPatients with CVID (Common Variable Immunodeficiency) or XLA (X-linked agammaglobulinemia) who:\n\nParticipated in the Phase III clinical study with intravenous IgPro10 (study number ZLB03\\_002CR) at 3- or 4- weekly intervals for 12 months (referred to as 'old' subjects)\n\nOR\n\nWere ≥ 6 years of age, were on other stable intravenous immunoglobulin therapy (200-800 mg IgG per kg body weight) at 3- or 4-week intervals for at least 6 months, AND were interested in participating in the Phase III clinical study with subcutaneous IgPro20 (study number ZLB04\\_009CR) (referred to as 'new' subjects)\n\nWritten informed consent\n\nKey Exclusion Criteria:\n\nDiagnosis of epilepsia\n\nInsulin dependent diabetes\n\nAdministration of steroids (daily ≥ 0.15 mg prednisone equivalent/kg/day) or other immunosuppressive drugs\n\nHistory of cardiac insufficiency (NYHA III/IV), cardiomyopathy, congestive heart failure, severe hypertension","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"71 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Proportion of Infusions With One or More Temporally-associated Adverse Events (AEs).","description":"AEs were considered temporally-associated AEs if they occurred during the infusion or in the period from the start of the infusion until either 48 or 72 hours after the end of the infusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.073","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.141","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.150","spread":null}]}]}]},{"type":"PRIMARY","title":"Influence of Infusion Rate on Temporally-Associated AEs","description":"The total and most frequent (1% or more) number of infusions for which subjects experienced temporally-associated AEs occurring within 72 hours of infusion, by infusion rate (≤ 4 mg/kg/min, ≤ 8 mg/kg/min, and \\> 8 and ≤ 12 mg/kg/min).\n\nAEs were considered to be temporally-associated AEs if they occurred in the period from the start of the infusion until 72 hours after the end of the infusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"153","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Rate of AEs by Severity and Relationship","description":"The AE rate was the number of AEs over the number of infusions administered.\n\nMild AEs: Did not interfere with daily activities; Moderate AEs: Interfered with routine daily activities; Severe AEs: Impossible to perform routine daily activities.\n\nAt least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.467","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.280","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.058","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.610","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.088","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.048","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.060","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.062","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.013","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.346","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.218","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.045","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Rate of Acute Serious Bacterial Infections.","description":"The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.\n\nAcute serious bacterial infections included pneumonia, bacteremia / septicemia, osteomyelitis / septic arthritis, bacterial meningitis, and visceral abscess.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.018","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Illness.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days of Hospitalization.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Rate of Any Infection.","description":"The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.\n\nInfections were classified as all AEs with the system organ class \"infections and infestations\" and AEs with the preferred term \"conjunctivitis\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.600","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Levels of Total Immunoglobulin (IgG) Serum Concentrations.","description":"Mean IgG trough concentration. For this analysis, each subject's values were first aggregated to their median and the median values were then analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.72","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Clinically Significant Changes in Vital Signs.","description":"Vital signs included heart rate, systolic blood pressure, diastolic blood pressure, and body temperature.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":55},"commonTop":["Headache","Sinusitis","Cough","Nausea","Diarrhea"]}}}